Skip to main content

DUPIXENT is indicated as an add-on maintenance treatment of adult patients with inadequately controlled
chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
Limitations of Use: DUPIXENT is not indicated for the relief of acute bronchospasm.

Not actual
DUPIXENT patients.

GIVE YOUR COPD
PATIENTS THE
OPPORTUNITY FOR
More I can moments

See the Impact of Dupixent Since Its Initial Approval

DUPIXENT is the only biologic that combines the ability to1-3:

Reduce
Exacerbations

Up to

34%

In NOTUS, annualized rate of moderate or severe exacerbations for DUPIXENT + triple therapy at Week 52 (0.86 exacerbations per year [n=470] vs 1.30 for placebo + triple therapy [n=465]. Rate ratio 0.66 (95% CI: 0.54, 0.82); P<0.001; primary endpoint)1,a

In BOREAS, 30% reduction (0.78 vs 1.10) in moderate or severe exacerbations for DUPIXENT + triple therapy (n=468) vs placebo + triple therapy (n=471) Rate ratio 0.70 (95% CI: 0.58, 0.86). P<0.001; primary endpoint1-3

LEARN MORE
ABOUT EXACERBATIONS

AND

Improve
Patients’ breathing and quality of life

Numerical improvement in
post-bronchodilator FEV1

BOREAS Trial
  • 158 mL numerical improvement for DUPIXENT + triple therapy (n=468) vs 84 mL for placebo + triple therapy (n=471) at Week 121

NOTUS Trial

  • 134 mL numerical improvement for DUPIXENT + triple therapy (n=470) vs 67 mL for placebo + triple therapy (n=465) at Week 121

Post-bronchodilator lung function results are descriptive. Definitive conclusions cannot be made.

Improvement in quality of life as measured by SGRQ1,2,4

BOREAS Trial

51% of patients reported a clinically meaningful (≥4-point) improvement in SGRQ scores at Week 52 with DUPIXENT + triple therapy vs 43% for placebo + triple therapy (N=939; OR: 1.44; 95% CI: 1.10, 1.89; P=0.009).

NOTUS Trial

  • 51% responder rate at Week 52 for subjects treated with DUPIXENT + triple therapy vs 47% for placebo + triple therapy (N=721; OR: 1.16; 95% CI: 0.86,1.58)1,6

NOTUS results are descriptive. Definitive conclusions cannot be made.

DISCOVER QoL DATA

AND

Target
TWO OF THE KEY DRIVERS OF TYPE 2 INFLAMMATION

IL-4 and IL-13 are two of the key drivers of local and systemic inflammation1

The mechanism of dupilumab action has not been definitively established.1

EXPLORE THE MOA

  • The most common adverse reactions (incidence ≥2%) are viral infection, headache, nasopharyngitis, back pain, diarrhea, arthralgia, urinary tract infection, local administration reaction, rhinitis, eosinophilia, toothache, and gastritis1
  • aModerate exacerbations were exacerbations that resulted in treatment with a systemic glucocorticoid, an antibiotic agent, or both. Severe exacerbations were exacerbations that led to hospitalization or an emergency department visit or that resulted in death.1-3

Post Hoc Data on COPD Exacerbations Leading to Hospital Visits Now Available

Explore the data
  • BOREAS Trial 30% reduction in the annualized rate of moderate or severe exacerbations for DUPIXENT + triple therapy (0.78 exacerbations per year [n=468] vs 1.10 for placebo + triple therapy [n=471]; rate ratio: 0.70 [95% CI: 0.58, 0.86] P<0.001)a
  • NOTUS Trial 34% reduction in the annualized rate of moderate or severe exacerbations for DUPIXENT + triple therapy (0.86 exacerbations per year [n=470] vs 1.30 for placebo + triple therapy [n=465]; rate ratio: 0.66 [95% CI: 0.54, 0.82] P<0.001)a

Number needed to treat (NNT):

Based on pooled analysis of BOREAS and NOTUS

For every

3 patients
on DUPIXENT,

Patients

1 moderate or severe
exacerbation was prevented5

  • The annualized rate of moderate or severe exacerbations for the DUPIXENT and placebo arms in the pooled analysis was 0.794 and 1.156, respectively (rate ratio 0.687, 95% CI 0.595, 0.793)

Definitive conclusions cannot be reached as the pre-specified pooled analysis was not controlled for multiplicity and the low exacerbation rate observed in the control group might limit the generalizability of our findings.

COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; OR, odds ratio; QoL, quality of life; SGRQ, St George’s Respiratory Questionnaire.

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and
offers financial assistance for eligible patients, one-on-one nursing support, and more.

LEARN HOW WE CAN HELP

DUPIXENT MyWay
ENROLLMENT FORMS
English Enrollment Form
Spanish Enrollment Form

Contact a Field Representative

Connect with a DUPIXENT Field Representative to get answers to your product-related questions.

contact a rep